Contineum Therapeutics, Inc.

Stage 4 · Declining · week 1

As of Oct 22, 2026, Contineum Therapeutics is in Stage 4, the downtrend phase, now in its first week (since Oct 21, 2026). It closed at $8.40, 52.2% below its 52-week high and below its 200-day average, which is falling.

$8.40

+0.54% today

$316M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CTNM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-04-05 → 2026-10-22

S? 42w

S4 26w

S2 12w

S3 11w

S2 12w

2024-04-052026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S4 26w → S1 8w → S2 10w → S3 4w → S2 2w → S3 3w → S2 12w → S3 11w → S2 12w → S3 3w → S4 1w current

Total tracked: 133 weeks across 12 stage runs.

CTNM among Biotechnology263rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…263	CTNMContineum Therapeutics, Inc.	Stage 4 · wk 1	37	−32.9%

vs 52W High

-52.2%

$7.08 lo$17.57 hi

52.2% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 1

1w13w26w

Week 1, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-38.2%

200 DMA: $13.59 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.54x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-32.9%

-40.3%

-32.4%

YTD

-26.3%

-24.1%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 1 · Vol 0.54x

2026-10-21S43→4

Wk 1 · Vol 1.09x

2026-10-20S3

Wk 3 · Vol 2.46x

2026-10-19S3

Wk 3 · Vol 2.07x

2026-10-16S3

Wk 3 · Vol 1.30x

2026-10-15S3

Wk 3 · Vol 1.22x

2026-10-14S3

Wk 3 · Vol 1.23x

2026-10-13S3

Wk 2 · Vol 3.40x

2026-10-12S3

Wk 2 · Vol 13.69x

2026-10-09S3

Wk 2 · Vol 1.46x

2026-10-08S3

Wk 2 · Vol 2.01x

2026-10-07S3

Wk 2 · Vol 1.23x

Moving averages & range

50 DMA

$13.45

200 DMA

$13.59

52W High

$17.57

52W Low

$7.08

5D Low

$7.08

Resistance levels (recent highs)

20d High

$13.42

60d High

$17.57

120d High

$17.57

250d High

$17.57

Next resistance

+59.9%

to 20d High

ROE

-28.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.3

Contineum Therapeutics: quick answers

What stage is Contineum Therapeutics in?

As of Oct 22, 2026, Contineum Therapeutics (CTNM) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 21, 2026 and is in its first week there. What the four stages mean

Is Contineum Therapeutics in an uptrend?

No. Contineum Therapeutics is in a Stage 4 downtrend. It trades 38.2% below its 200-day average, which is falling.

How far is Contineum Therapeutics from its 52-week high?

Contineum Therapeutics closed at $8.40 on Oct 22, 2026, 52.2% below its 52-week high of $17.57. Its 52-week low is $7.08.

How has Contineum Therapeutics performed over the past year?

As of Oct 22, 2026, Contineum Therapeutics is down 24.1% over the past year and down 26.3% so far in 2026.

Which sector and industry is Contineum Therapeutics in?

Contineum Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.